环丙沙星靶向再治疗未完全缓解的慢阻肺急性加重:双盲随机安慰剂对照多中心III期试验
针对慢阻肺急性加重后14天症状持续和/或血清C反应蛋白≥8 mg/L的未完全缓解患者,再给予口服环丙沙星500 mg每日两次共7天,与安慰剂相比未延长至下一次加重的时间。90天内两组加重比例相近,中位至下次加重时间无显著差异,生活质量与肺功能亦无差异。
要点
- 慢阻肺急性加重14天未完全缓解者再加用环丙沙星7天无额外获益
- 主要终点至下次加重时间无显著差异(校正HR 1.07,95%CI 0.68-1.68,P=0.76)
- 未完全缓解的急性加重可能非持续细菌感染驱动,或可考虑抗炎治疗
核心结论
- 对慢阻肺急性加重后14天症状持续和/或CRP≥8 mg/L的患者,额外口服环丙沙星500 mg每日两次共7天较安慰剂无额外获益。
- 提示未完全缓解的急性加重并非由持续细菌感染驱动,可能适合以抗炎治疗为靶点。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照III期临床试验(NCT02300220)。
- 筛查826例,随机144例GOLD II-IV期慢阻肺且未完全缓解者,环丙沙星组n=72、安慰剂组n=72。
- 再治疗于索引急性加重后14(±3)天启动,口服环丙沙星500 mg或匹配安慰剂每日两次共7天。
主要发现
- 随机后90天内,环丙沙星组57%、安慰剂组53%的患者经历一次或以上急性加重。
- 至下次加重中位时间:安慰剂组32.5天(四分位距13-50),环丙沙星组34天(四分位距17-62),无显著差异(校正HR 1.07;95%CI 0.68-1.68;P=0.76)。
- 两组生活质量评分与肺功能无显著差异。
临床怎么用
- 对急性加重后14天症状持续和/或CRP≥8 mg/L者,不应常规再加用环丙沙星7天。
- 此类未完全缓解事件可考虑抗炎治疗方向而非继续抗菌治疗。
局限性
- 研究仅涉及四个中心、144例随机患者,样本量有限。
- 再治疗方案限定为环丙沙星500 mg每日两次共7天,结果不外推至其他药物或疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are prone to nonrecovery, but there are no data about the effectiveness of retreatment for these prolonged events. We examined whether further therapy with ciprofloxacin for incompletely resolved COPD exacerbations prolonged the time until the next event.Objectives: To assess whether incompletely recovered COPD exacerbations benefit from additional treatment with ciprofloxacin, at Day 14.Methods: In a multicenter, randomized double-blind placebo-controlled trial, we studied retreatment with oral ciprofloxacin 500 mg or matched placebo twice daily for 7 days in patients with Global Initiative for Chronic Obstructive Lung Disease stage II-IV COPD and persistent symptoms and/or serum C-reactive protein ≥8 mg/L initiated 14 (±3) days after an index COPD exacerbation. The primary outcome was the time to the next exacerbation within a 90-day period.Measurements and Main Results: Among 826 patients screened at four centers, 144 eligible participants with incomplete recovery were randomized to receive ciprofloxacin (n = 72) or placebo (n = 72). Within 90 days of randomization, 57% of the patients in the ciprofloxacin group and 53% in the placebo group experienced one or more exacerbations. The median time to the next exacerbation was 32.5 days (interquartile range 13-50) in the placebo arm and 34 days (interquartile range 17-62) in the ciprofloxacin arm, which was not significantly different (adjusted hazard ratio, 1.07; 95% confidence interval, 0.68-1.68; P = 0.76). No significant differences were seen in quality-of-life scores or lung function between the treatment groups.Conclusions: In patients with persistent symptoms and/or raised C-reactive protein 14 days after a COPD exacerbation, an additional course of ciprofloxacin resulted in no additional benefit compared with placebo. This suggests that nonrecovered exacerbations are not driven by ongoing bacterial infection and may potentially be targeted with antiinflammatory therapy.Clinical trial registered with www.clinicaltrials.gov (NCT02300220).
引用
- Ritchie AI, Brill SE, Vlies BH, et al. Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial. Am J Respir Crit Care Med. 2020. PMID: 32267724. doi:10.1164/rccm.201910-2058OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。